Entering text into the input field will update the search result below

Early-stage study shows potential expanded therapeutic window for Minerva's roluperidone

Nov. 19, 2018 10:05 AM ETMinerva Neurosciences, Inc. (NERV) StockBy: Douglas W. House, SA News Editor
  • Results from a Phase 1 single-escalating dose study of Minerva Neurosciences' (NASDAQ:NERV +1%) schizophrenia candidate MIN-101 (roluperidone) showed a favorable safety profile and possibly an expanded therapeutic window.
  • It says the data suggest that roluperidone may be effective in treating schizophrenia patients with psychosis at higher doses than those being used in the Phase 3 study.
  • Topline data from the Phase 3 trial should be available in mid-2019. A previously announced Phase 2b study was successful.
  • The company will host a key opinion leader (KOL) event tomorrow, November 20, in New York to discuss roluperidone and its potential use in treating negative symptoms of schizophrenia.

Recommended For You

More Trending News

About NERV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NERV--
Minerva Neurosciences, Inc.